Vyvanse™ (lisdexamfetamine dimesylate) CII Rx Only

INDICATIONS AND USAGE
Vyvanse™ is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of Vyvanse in the treatment of ADHD has been established on the basis of two controlled trials in children aged 6 to 12 and one controlled trial in adults who met DSM-IV-TR® criteria for ADHD. Vyvanse is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social).

Long-Term Use
The effectiveness of Vyvanse for long-term use, i.e., for more than 4 weeks, has not been systematically evaluated in controlled trials. The physician should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

CONTRAINdications
Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncratic reaction to sympathomimetic amines, glaucoma. Agitated states. Patients with a history of drug abuse or drug withdrawal within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crisis may result).

WARNINGS AND PRECAUTIONS
Serious Cardiovascular Events
Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems: In the pediatric literature, a number of cases of sudden death or near sudden death in children and adolescents with structural cardiac abnormalities or other serious heart problems have been reported. Children and adolescents with a history of cardiovascular abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug, and those with such abnormalities who also generally not be treated with stimulant drugs.

Hypertension and Other Cardiovascular Conditions: Stimulant medications may cause a modest increase in average blood pressure (about 2-4 mm Hg) and average heart rate (about 3-6 bpm) and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Clinically significant changes in heart rate or blood pressure (e.g. palpitations, tachycardia, hypertension) and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also be treated with stimulant drugs.

Pre-existing Psychosis: Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Prior to initiating treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.

Psychiatric Adverse Events
Pre-existing Psychosis: Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Bipolar Illness: Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be carefully observed and, if necessary, treated to determine if they are at risk for bipolar disorder. Such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder and depression.

Emergence of New Psychotic or Manic Symptoms: Treatment-emergent psychiatric symptoms, including manic symptoms ormania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) or stimulant-treated patients compared to 0 in placebo-treated patients.

Agitation: Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience. The behavior may appear appropriate or inappropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) or stimulant-treated patients compared to 0 in placebo-treated patients.

Visual Disturbance
Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.

Amphetamines have been reported to exacerbate motor and phonic tics and Tourette’s syndrome. Therefore, clinical evaluation for tics and Tourette’s syndrome should precede use of stimulant medications.

Long-Term Suppression of Growth
Careful follow-up for weight in children ages 6 to 12 who received Vyvanse over 12 months suggests that consistently medicated children (i.e. treatment for 7 days per week throughout the year) have a slowing in growth rate, measured by body weight as demonstrated by an age- and sex-normalized mean change from baseline in percentile, of -13.4 over 1 year (average percentile at baseline and 12 months, were 50.8 and 47.2, respectively). Therefore growth should be monitored during treatment with stimulants, and patients who are not growing or gaining weight as expected may need to have their treatment interrupted.

Prescribing and Dispensing
The total amount of stimulatable feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdose. Vyvanse should be used with caution in patients who use other sympathomimetic drugs.

ADVERSE REACTIONS
Clinical Studies Experience
The postmarketing development program for Vyvanse included exposures in a total of 762 participants in clinical trials (348 pediatric patients, 358 adult patients and 56 healthy adult subjects).

In the controlled pediatric (aged 6 to 12) trial, 10% (21/218) of Vyvanse-treated patients discontinued due to adverse reactions compared to 1% (1/72) who received placebo. The most frequent adverse events leading to discontinuation and considered to be drug-related (i.e. leading to discontinuation in at least 1% of Vyvanse-treated patients and at a rate at least twice that of placebo) were ECG changes (1%, increase in QT interval, cardiac evaluation); psychiatric disorder, psychomotor hyperactivity, insomnia, and rash (2/218 each; 1%). The most common adverse reactions (incidence ≥5% and at a rate at least twice placebo) were decreased appetite, dizziness, dry mouth, irritability, insomnia, upper abdominal pain, nausea, vomiting and decreased weight.

In the controlled adult trial, 6% (21/358) of Vyvanse-treated patients discontinued due to adverse events compared to 2% (1/62) who received placebo. The most frequent adverse events leading to discontinuation and considered to be drug-related (i.e. leading to discontinuation in at least 1% of Vyvanse-treated patients and at a rate at least twice that of placebo) were insomnia (9/358; 2%); tachycardia (3/358; 1%), tachycardia (2/358; 1%); hypertension (4/358; 1%), headache (2/358; 1%); anxiety (2/358; 1%), and dyspnea (3/358; 1%). The most common adverse reactions (incidence ≥5% and at a rate at least twice placebo) were upper abdominal pain, diarrhea, nausea, fatigue, feeling jittery, irritability, anorexia, decreased appetite, headaches, anxiety and insomnia.

Postmarketing Reports
The following adverse reactions have been identified during post approval use of Vyvanse:

Cardiac Disorders: Palpitation
Eye Disorders: Vision blurred, mydriasis
Immune System Disorders: Hypersensitivity
Nervous System Disorders: Seizure, dyskinesia
Psychiatric Disorders: Psychotic episodes, mania, hallucination, depression, aggression, dysphoria, euphoria, logorrhea
Skin and Appendages Disorders: Angioedema, urticaria

USE IN SPECIFIC POPULATIONS
Pregnancy: Pregnancy Category C. Amphetamines should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.

Pediatric Use: Vyvanse has not been studied in children under 6 years of age or adolescents. Amphetamines are not recommended for use in children under 3 years of age.

Geriatric Use: Vyvanse has not been studied in the geriatric population.

DRUG ABUSE AND DEPENDENCE
Vyvanse is classified as a Schedule II controlled substance.

OVERDOSAGE
Toxic symptoms may occur idiosyncratically at low doses. Treatment: Consult with a Certified Poison Control Center for up-to-date guidance and advice. The prolonged release of Vyvanse in the body should be considered when treating patients with overdosage.

Last Modified: 11/2008 VYV-00104

Shire

https://doi.org/10.1017/S109285290002006X Published online by Cambridge University Press
Important Safety Information

Vyvanse should not be taken by patients who have advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; known hypersensitivity or idiosyncrasy to sympathomimetic amines; agitated states; glaucoma; a history of drug abuse; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD. Physicians should take a careful patient history, including family history, and physical exam, to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated. Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.

New psychosis, mania, aggression, growth suppression, and visual disturbances have been associated with the use of stimulants. Use with caution in patients with a history of psychosis, seizures or EEG abnormalities, bipolar disorder, or depression. Growth monitoring is advised during prolonged treatment.

Amphetamines have a high potential for abuse. Administration of amphetamines for prolonged periods of time may lead to drug dependence. Particular attention should be paid to the possibility of subjects obtaining amphetamines for non-therapeutic uses or distribution to others and the drugs should be prescribed or dispensed sparingly. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events.

The most common adverse events reported in clinical studies of Vyvanse were: pediatric – decreased appetite, insomnia, abdominal pain, and irritability; adult – decreased appetite, insomnia, and dry mouth.

Please see Brief Summary of Full Prescribing Information, including Boxed Warning, on adjacent page.